Clozapine is an atypical antipsychotic indicated for:
Treatment-resistant schizophrenia. Efficacy was established in an active-controlled study.
Reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder. Efficacy was established in an active-controlled study.
Hypersensitivity to the active substance or to any of the excipients.
Patients unable to undergo regular blood tests.
History of toxic or idiosyncratic granulocytopenia/agranulocytosis (with the exception of granulocytopenia/agranulocytosis from previous chemotherapy).
History of Clozapine-induced agranulocytosis.
Clozapine treatment must not be started concurrently with substances known to have a substantial potential for causing agranulocytosis; concomitant use of depot antipsychotics is to be discouraged
Impaired bone marrow function.
Uncontrolled epilepsy.
Alcoholic and other toxic psychoses, drug intoxication, comatose conditions.
Circulatory collapse and/or CNS depression of any cause.
Severe renal or cardiac disorders (e.g. myocarditis).
Active liver disease associated with nausea, anorexia or jaundice; progressive liver disease, hepatic failure.
Paralytic ileus